Physicians have now treated over 1,000 patients with the Vici Venous Stent. The product received CE mark in October 2013 and was first implanted in January 2014. Subsequently, it has been launched in 13 countries worldwide. Veniti says that the stent design allows the physician to confidently treat the millions of patients suffering from chronic venous disease associated with venous outflow obstruction.
At one of the busiest and advanced centres for deep venous therapy, Michael KW Lichtenberg, chief of Angiology Clinic and Venous Center, Klinikum Arnsberg, Arnsberg, Germany, has performed more than 100 deep venous interventions thus far in 2016.
“Despite the vigilance we have for the symptoms of chronic venous disease and venous outflow obstruction, I am continually amazed by the incidence of venous outflow obstruction and the impact it has on our patients. Having a stent designed for the venous anatomy, like the Vici Venous Stent, contributes to our ability to provide the care they need,” said Lichtenberg. “What has been most satisfying is the rapid resolution of patients’ symptoms and improvement in their quality of life. It is critical that all physicians be aware of the roles of reflux and obstruction in venous disorders.”
Veniti is currently conducting the VIRTUS trial to evaluate the safety and efficacy of the Vici stent for the treatment of chronic iliofemoral venous outflow obstruction under a US Food and Drug Administration Investigational Device Exemption.
“The challenges of the venous system are unique,” said Jeff Elkins, president and chief executive officer of Veniti. “The achievement of this milestone with the Vici Venous Stent is testimony to an excellent performance profile across a wide range of patients among varied practitioners in the real world. We are committed to further perfect our results through clinical and technical research.”